United States was TherapeuticsMD’s largest region in fiscal 2025, bringing in $1.79M of $3.02M (59%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $1.00M | $1.12M | $1.79M |
| Non-U.S | $299.00K | $638.00K | $1.23M |
| Total | $1.30M | $1.76M | $3.02M |
TherapeuticsMD brought in $3.02M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 71.6% from $1.76M in fiscal 2024. United States was the largest at $1.79M (59.3%), ahead of Non-U.S at $1.23M (40.7%).
Compared with fiscal 2024, Non-U.S grew 92.8% to $1.23M and United States grew 59.6% to $1.79M. From fiscal 2023 to 2025, combined revenue from these regions grew from $1.30M to $3.02M, a compound annual growth rate of 52.3%. United States' share of the total fell from 77.0% to 59.3%.
TherapeuticsMD (TXMD) reports its revenue by geography. In fiscal 2025, United States was its largest region, bringing in $1.79M (59.3% of the total), followed by Non-U.S at $1.23M (40.7%).
United States was TherapeuticsMD's largest region in fiscal 2025, bringing in $1.79M, or 59.3% of the $3.02M total across its two regions.
Non-U.S grew faster than United States in fiscal 2025, up 92.8% from $638.00K to $1.23M. United States grew 59.6% to $1.79M.
Every figure comes from TherapeuticsMD's annual financial filings, as reported. Each line keeps the name TherapeuticsMD gives it, and years follow its fiscal calendar.
TherapeuticsMD's revenue by geography goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.